Masimo Taps Katie Szyman

After its longtime chief was ousted last year following a proxy battle, Masimo has now appointed a new CEO. | The medtech has ...
Masimo (NASDAQ:MASI – Get Free Report)‘s stock had its “hold” rating reaffirmed by equities research analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports.
Needham analyst Michael Matson has maintained their neutral stance on MASI stock, giving a Hold rating on January 17.Invest with Confidence: ...
Today the Board of Directors (the “Board”) of Masimo (NASDAQ: MASI), a leading global medical innovator, announced that Katie Szyman has been appointe ...
Looking ahead to 2025, Masimo projects healthcare revenues to land between $1.5 billion and $1.53 billion. That would deliver ...
Piper Sandler analyst Jason Bednar maintained a Buy rating on Masimo (MASI – Research Report) today and set a price target of $210.00. The ...
MASI's revenue growth in the fourth quarter is likely to have been boosted by the continued robust adoption of its products.